Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: Insights from a Cyp2a(4/5)bgs-Null Mouses

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 746-754

  Li, Lei ^a   Jia, Kunzhi ^a   Zhou, Xin ^a   McCallum, Sarah E ^b   Hough, Lindsay B ^b   Ding, Xinxin ^a  

^a WADSWORTH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; CYTOCHROME P450 2A; CYTOCHROME P450 2A5; CYTOCHROME P450 2B; LIVER ENZYME; NICOTINE; NICOTINE DEHYDROGENASE; NICOTINE TARTRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CYP2A GENE; CYP2B GENE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER MICROSOME; MALE; MOUSE; NICOTINE METABOLISM; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; SINGLE DRUG DOSE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CONDITIONING, OPERANT; HALF-LIFE; IMMERSION; MALE; MICE; MICE, KNOCKOUT; NICOTINE; NICOTINIC AGONISTS; PAIN MEASUREMENT; REACTION TIME; REWARD; STEROID HYDROXYLASES;

EID: 84887897881     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208256     Document Type: Article

References (30)

1. Acquas E, Carboni E, Leone P., and Di Chiara G (1989) SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacology (Berl) 99:151-155. (Pubitemid 19215210)
2. Amos CI, Spitz MR, and Cinciripini P (2010) Chipping away at the genetics of smoking behavior. Nat Genet 42:366-368.
3. Audrain-McGovern J., Al Koudsi N, Rodriguez D, Wileyto E.P., Shields PG, and Tyndale RF (2007) The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 119:e264-e274. (Pubitemid 46397834)
4. Corrigall WA, Franklin KB, Coen K.M., and Clarke PB (1992) The mesolimbic dopa-minergic system is implicated in the reinforcing effects of nicotine. Psychophar-macology (Berl) 107:285-289.
5. Cunningham CL, Gremel CM, and Groblewski PA (2006) Drug-induced conditioned place preference and aversion in mice. Nat Protoc 1:1662-1670. (Pubitemid 46773287)
6. Damaj MI, Siu EC, Sellers E.M., Tyndale RF, and Martin BR (2007) Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257. (Pubitemid 46025741)
7. Ekins S, Iyer M, Krasowski M.D., and Kharasch ED (2008) Molecular characterization of CYP2B6 substrates. Curr Drug Metab 9:363-373. (Pubitemid 352025191)
8. Faraday MM, Blakeman KH, and Grunberg NE (2005) Strain and sex alter effects of stress and nicotine on feeding, body weight, and HPA axis hormones. Pharmacol Biochem Behav 80:577-589. (Pubitemid 41583206)
9. Ferguson CS and Tyndale RF (2011) Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 32:708-714.
10. Grabus SD, Martin BR, Batman A.M., Tyndale RF, Sellers E, and Damaj MI (2005) Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) 178:183-192. (Pubitemid 40379213)
11. Grabus SD, Martin BR, Brown S.E., and Damaj MI (2006) Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nico-tinic receptor antagonists. Psychopharmacology (Berl) 184:456-463. (Pubitemid 43255862)
12. Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559-603. (Pubitemid 28285583)
13. Hough LB, de Esch IJ, Janssen E, Phillips J, Svokos K., Kern B, Trachler J, Abood M.E., Leurs R., and Nalwalk JW (2006) Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology 51:447-456. (Pubitemid 44215952)
14. Hukkanen J, Jacob P, 3rd, and Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79-115. (Pubitemid 40283970)
15. Karp I, O'Loughlin J, Hanley J, Tyndale R.F., and Paradis G (2006) Risk factors for tobacco dependence in adolescent smokers. Tob Control 15:199-204. (Pubitemid 43864875)
16. Khokhar JY and Tyndale RF (2011) Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuro-psychopharmacology 36:692-700.
17. Matta SG, Balfour DJ, Benowitz N.L., Boyd RT, Buccafusco JJ, Caggiula AR, Craig C.R., Collins AC, Damaj MI, and Donny EC, et al (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 190:269-319. (Pubitemid 46156883)
18. Miksys S, Lerman C, Shields P.G., Mash DC, and Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuro-pharmacology 45:122-132. (Pubitemid 36700458)
19. Miksys SL and Tyndale RF (2002) Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27:406-415. (Pubitemid 36110781)
20. O'Loughlin J., Paradis G, Kim W., DiFranza J, Meshefedjian G, McMillan-Davey E, Wong S., Hanley J, and Tyndale RF (2004) Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 13: 422-428. (Pubitemid 39635932)
21. Ray R, Tyndale RF, and Lerman C (2009) Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 23: 252-261.
22. Sewell RD and Spencer PS (1976) Antinociceptive activitiy of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats. Neuropharmacology 15:683-688.
23. Siu EC and Tyndale RF (2007) Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol 71:826-834. (Pubitemid 46294094)
24. Siu EC, Wildenauer DB, and Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184:401-408. (Pubitemid 43255856)
25. Statler PA, McPherson RJ, Bauer L.A., Kellert BA, and Juul SE (2007) Pharmacoki-netics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 61:671-675. (Pubitemid 46800274)
26. Wassenaar CA, Dong Q, Wei Q., Amos CI, Spitz MR, and Tyndale RF (2011) Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 103:1342-1346.
27. Wei Y, Li L, Zhou X., Zhang QY, Dunbar A, Liu F, Kluetzman K., Yang W, and Ding X (2013) Generation and characterization of a novel Cyp2a(4/5)bgs-null mouse model. Drug Metab Dispos 41:132-140.
28. Yamazaki H, Inoue K, Hashimoto M., and Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73: 65-70. (Pubitemid 29226163)
29. Zhang Y, Huo M, Zhou J., and Xie S (2010) PKSolver: An add-in program for phar-macokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306-314.
30. Zhou X, Zhuo X, Xie F., Kluetzman K, Shu YZ, Humphreys W.G., and Ding X (2010) Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther 332:578-587.